Pay in 4 interest-free payments of $6.52 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Legal Basis for the Claims Failure to warn the label and marketing did not adequately disclose the risk of ileus and bowel obstruction Negligent design and testing semaglutide was not adequately evaluated for long-term gastrointestinal safety before release Off-label promotion marketing for weight loss to patients without diabetes, raising informed consent questions Strict product liability the drug was unreasonably dangerous given the warnings provided Note that in California, prescription drug manufacturers are not strictly liable for design defect under Brown v
In the SURPASS clinical trial program for type 2 diabetes, diarrhea occurred in approximately 12-16% of patients receiving tirzepatide across various doses (5 mg, 10 mg, and 15 mg weekly), compared to lower rates in comparator groups
Additionally, there is a risk of peptide-related impurities and API characterization as the drug is not regulated by the FDA
A partner may feel insecure or jealous if the other person is losing weight quickly
For most medications, this doesn't matter clinically
One user on Tik Tok writing, Bought it, tried it, & it does actually work
US$ 28.10
US$ 28.06
US$ 24.40
